ADVERTISEMENT
Delix Partners With NIDA to Study Ibogaine Analog to Treat Multiple SUDs
Delix Therapeutics on Tuesday announced a new partnership with the National Institute on Drug Abuse (NIDA) to study the use of one of its lead clinical candidates—a non-hallucinogenic and non-toxic ibogaine analog—to treat a range of substance use disorders. Research will be conducted under NIDA’s Addiction Treatment Discovery Program, which works with industry partners to conduct preclinical screening, evaluating pharmacotherapies as treatments for the medical management of substance use disorders.
A notable aspect of the analog, known as DLX-7, is that previous research has shown it to be potentially capable of treating multiple substance use disorders; research published last year in the journal Nature demonstrated a reduction of alcohol- and heroin-seeking behaviors.
In a news release announcing the NIDA partnership, the Boston-based Delix noted that its most advanced compounds have been shown to produce both fast-acting and long-lasting rewiring of neural circuitry associated with depression and other psychiatric disorders, without in-clinic care, safety issues, or the abuse potential associated with other neural plasticity-promoting compounds.
Delix expects to have initial data from NIDA’s research on DLX-7 in early 2022.
